Who Paid My Doc
Jonathan Claud
Emergency Medicine Lisle, IL
NPI 1407880958 CMS profile 1171916
430 Warrenville Rd Ste 230, Lisle, IL 60532
General payments
$0
Research payments
$0
Ownership & investment interest
$0
The CMS Open Payments record contains no reported payments to Jonathan Claud of Lisle, IL.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.
Prescribing to Medicare patients
Part D · data year 2024 · 18 drugsPart D claims
565
Drug cost
$3,066
Branded share of claims
18.9%
| Drug | Type | Relative to their largest | Claims | Drug cost |
|---|---|---|---|---|
| Azithromycin | Generic | 112 | $397 | |
| Amoxicillin-Clavulanate Potass Amoxicillin/Potassium Clav | Brand | 40 | $391 | |
| Cefadroxil | Generic | 60 | $388 | |
| Doxycycline Hyclate | Generic | 43 | $305 | |
| Cephalexin | Generic | 48 | $253 | |
| Fluticasone Propionate | Generic | 23 | $252 | |
| Oseltamivir Phosphate | Generic | 12 | $190 | |
| Mupirocin | Generic | 18 | $157 | |
| Nitrofurantoin Mono-Macro Nitrofurantoin Monohyd/M-Cryst | Brand | 16 | $125 | |
| Ondansetron Odt Ondansetron | Brand | 15 | $112 |
The 10 drugs with the highest cost, of 18 counted.
Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 40,243 Part D prescribers listed as Emergency Medicine; they describe a distribution and say nothing about conduct.
Billing to Medicare
Part B · data year 2024 · 72 billing codesPaid by Medicare
$91,341
Medicare patients
509
Services billed
1,573
| Condition among their Medicare patients | Relative to the most common | Share of patients |
|---|---|---|
| High blood pressure | 69% | |
| Arthritis | 46% | |
| Ischemic heart disease | 30% | |
| Chronic kidney disease | 23% | |
| Osteoporosis | 21% | |
| Atrial fibrillation | 20% | |
| Cancer | 18% | |
| Diabetes | 17% |
| Drug given in the clinic | Where | Patients | Services | Paid by Medicare |
|---|---|---|---|---|
| Infusion, normal saline solution, sterile (500 ml = 1 unit) J7040 | Office | 42 | 46 | $47 |
| Injection, ceftriaxone sodium, per 250 mg J0696 | Office | 12 | 60 | $21 |
Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.
Other Emergency Medicine in Illinois
Related records
Emergency Medicine in Illinois
Practitioners in the same specialty and state, ranked by reported value.
All Emergency Medicine
Everyone recorded under this specialty, nationwide.
Doctors in Illinois
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.